Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
All
Crypto
Stocks
Commodities & Forex
Macro
NEAR’s Stablecoin Market Cap Soars 717% over the last 6 months
NEAR’s Stablecoin Market Cap Soars 717% over the last 6 months

Share link:In this post: NEAR’s stablecoin market cap has surged in the last few months. NEAR’S active addresses have also been augmented, and the foundation currently boasts over 100 million addresses. In Q2 2024, 50% of the total NEAR’s circulation was staked, with the annualized actual yield at 4.5%.

Cryptopolitan·2024/08/15 16:00
Why is Bitcoin stuck at $58K?
Why is Bitcoin stuck at $58K?

Share link:In this post: Bitcoin’s price falls as demand for leveraged long BTC futures and stablecoins declines. Glassnode data shows Bitcoin holders behavior appears to be moving back towards HODLing and accumulation. Bitcoin will fall further below $58K before making a trade comeback.

Cryptopolitan·2024/08/15 16:00
Bitcoin Plummets to $56K and Recovers, Altcoins Volatile (Market Watch)
Bitcoin Plummets to $56K and Recovers, Altcoins Volatile (Market Watch)

Bitcoin bulls were quick to react, but the market sentiment remains fearful.

Cryptopotato·2024/08/15 16:00
Tron network’s 90-day revenue surges past Ethereum’s revenue
Tron network’s 90-day revenue surges past Ethereum’s revenue

Tron network gained $1.31 million in revenue in the last 24 hours. Tron fees revenue reached over $435 million, exceeding Ethereum’s fees of nearly $364 million over a 90-day period. Tron’s 30-day revenue surpassed Ethereum’s revenue by almost 50%.

Cryptopolitan·2024/08/15 16:00
Flash
20:57
US Dollar Index Falls 0.09% on 16th
The US Dollar Index fell 0.09% on the 16th, closing at 99.540 in the foreign exchange market.
20:48
According to a document submitted to the U.S. Securities and Exchange Commission, an agreement between Arvinas Holding Company LLC and Pfizer indicates that both parties are eligible for milestone payments totaling up to 320 millions USD, along with a tiered royalty structure.
The document further clarifies the conditions and specific terms that trigger payment. Milestone payments will be distributed in phases based on the progress of R&D in the collaborative project, regulatory approvals, and commercialization outcomes at different stages. Tiered royalties mean that as product sales reach different thresholds, the rates will be adjusted accordingly, providing both parties with a more flexible revenue-sharing mechanism. This financial arrangement highlights both parties' confidence in the project's prospects and reflects the risk-sharing and profit-sharing models commonly seen in the biopharmaceutical industry. Although the details of the agreement have not been fully disclosed, the total potential revenue of up to $320 million undoubtedly injects strong financial momentum into the subsequent development of the project.
20:48
According to a filing submitted to the U.S. Securities and Exchange Commission, biotechnology company Arvinas Holding Company LLC, pharmaceutical giant Pfizer, and Rigel Pharmaceuticals obtained approval under the Hart–Scott–Rodino Antitrust Improvements Act on June 11, 2026.
This key development has removed regulatory obstacles for all parties to advance the previously announced licensing agreement. The conclusion of this agreement marks a new substantive phase in the related cooperation. Passing the HSR antitrust review is a crucial step in strategic collaborations involving intellectual property and market access. This usually means that regulatory authorities have determined the transaction will not materially harm competition in the relevant market. With this regulatory threshold crossed, all parties are expected to accelerate implementation of the detailed terms of the licensing agreement, boosting progress in related R&D or commercialization projects. This dynamic is being closely watched by industry observers.
News